65,437 trials
Spinocerebellar Ataxias · Spinocerebellar Ataxia Genotype Type 1 · Spinocerebellar Ataxia Genotype Type 2
Primary: Change From Baseline in Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) at Randomization Phase Week 8 — -0.810; -1.059 score on a scale — p=0.519
Breast Neoplasm
Primary: Objective Response Rate (ORR) — 25.8; 21.8; 23.4 percentage of participant
Diabetic Peripheral Neuropathy
Primary: Balance Test (BalanSense Device) — 1.54; 1.72; 1.76; 1.94 degrees^2
Adverse Event Following Immunisation
Primary: Number of Subjects Experiencing SAEs, Severe AEs (Grade 3), and/or IMEs — 0; 1 Participants
Chronic Spontaneous Urticaria
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (AE) — 190 Participants
Partial-thickness Burn · Ulcer
Primary: Number of Participants Who Achieved Complete Wound Healing — 15; 19; 14 Participants
Bleeding
Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275
Femoroacetabular Impingement
Primary: Hip Outcome Score - ADL Subscale at 24 Months — 69.3; 73.1 score on a scale
Non-cystic Fibrosis Bronchiectasis
Primary: Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs) — 6.80; 7.67; 6.10; 6.98 log10 CFUs
Colitis, Ulcerative
Primary: Remission Rate — 2; 1; 2 Participants
Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour) · Hypertension
Primary: Change in Muscle Sympathetic Nerve Activity Responses During Hypoxia — -0.54; -0.84; -0.71; -0.69 bursts/minute*%SaO2
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal…
Heart Failure
Primary: Freedom From Device/System Related Complications — 98.3 percentage of patients
Dental Caries
Primary: Observed Fluoride Urinary Recovery — 1.29 mg
Advanced Cancer
Primary: Best Response Following Extended Use of CS-7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Participants With Cancer — 0; 1; 1; 0 Participants